We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
Cap. Flow
+$76.2M
Cap. Flow %
1.6%
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$190M
2
INSM icon
Insmed
INSM
+$168M
3
GILD icon
Gilead Sciences
GILD
+$130M
4
UTHR icon
United Therapeutics
UTHR
+$105M
5
BBIO icon
BridgeBio Pharma
BBIO
+$81.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$121M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.6M
3
RVMD icon
Revolution Medicines
RVMD
+$72.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$63.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.05%
3 Technology 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$240B
$308M 6.49%
851,550
+556,192
+188% +$190M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$141B
$287M 6.05%
578,634
-103,274
-15% -$45.8M
ARGX icon
3
argenx
ARGX
$65.9B
$279M 5.88%
301,000
-12,000
-4% -$9.9M
GILD icon
4
Gilead Sciences
GILD
$188B
$273M 5.74%
2,158,772
+988,893
+85% +$130M
RVMD icon
5
Revolution Medicines
RVMD
$45.2B
$196M 4.13%
1,048,014
-496,442
-32% -$72.5M
ORKA
6
Oruka Therapeutics
ORKA
$6.02B
$158M 3.32%
1,657,190
+1,150,182
+227% +$76.6M
INSM icon
7
Insmed
INSM
$27.7B
$149M 3.13%
1,393,418
+1,383,384
+13,787% +$168M
SRRK icon
8
Scholar Rock
SRRK
$6.81B
$135M 2.83%
2,449,547
-1,135,026
-32% -$54.8M
NUVL
9
DELISTED
Nuvalent
NUVL
$130M 2.74%
1,053,268
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.6B
$124M 2.6%
6,731,909
+5,765
+0.1% +$92.9K
RLAY icon
11
Relay Therapeutics
RLAY
$4.17B
$116M 2.44%
6,185,970
-1,609,272
-21% -$23.4M
PCVX icon
12
Vaxcyte
PCVX
$9.1B
$115M 2.41%
1,971,935
+781,238
+66% +$42.4M
UTHR icon
13
United Therapeutics
UTHR
$21B
$102M 2.15%
188,515
+186,438
+8,976% +$105M
ISRG icon
14
Intuitive Surgical
ISRG
$131B
$101M 2.13%
254,809
-31,845
-11% -$13.9M
REGN icon
15
Regeneron Pharmaceuticals
REGN
$86.8B
$98.1M 2.06%
157,291
-121,383
-44% -$82.6M
CRNX
16
DELISTED
Crinetics Pharmaceuticals
CRNX
$98M 2.06%
2,620,000
-660,000
-20% -$24.5M
BBIO icon
17
BridgeBio Pharma
BBIO
$14.7B
$88.6M 1.86%
1,189,506
+1,164,129
+4,587% +$81.5M
IMCR icon
18
Immunocore
IMCR
$1.93B
$88.5M 1.86%
2,788,245
-8,558
-0.3% -$253K
ABT icon
19
Abbott
ABT
$188B
$85.9M 1.81%
947,115
-204,520
-18% -$18.7M
SYK icon
20
Stryker
SYK
$118B
$84.5M 1.78%
268,461
+51,224
+24% +$16.1M
MDT icon
21
Medtronic
MDT
$119B
$77.8M 1.64%
994,233
+36,904
+4% +$2.98M
IONS icon
22
Ionis Pharmaceuticals
IONS
$9.66B
$77.1M 1.62%
972,258
-846,407
-47% -$63.7M
ELVN icon
23
Enliven Therapeutics
ELVN
$4.37B
$75.6M 1.59%
1,490,000
-830,867
-36% -$35.3M
VERA icon
24
Vera Therapeutics
VERA
$2.52B
$73.4M 1.54%
1,710,808
+37
+0% +$1.38K
JBIO
25
Jade Biosciences
JBIO
$1.26B
$67.9M 1.43%
3,057,996
-443,506
-13% -$9.25M
1
2 3 4 5

Similar funds

SP
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
NHC
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Bellevue Group's Q2 2026 Portfolio in Review

As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Technology.

  • Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
  • Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
  • Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
  • Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
  • Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.